Venture firms pour $101M into a biotech using the brain to fix the immune system

Nilo Therapeutics, which launched Wednesday, is trying to develop drugs that regulate inflammation and the immune system by targeting a special kind of nerve cell.

Zenas looks to China to stock pipeline with 3 more immune drugs

A potentially $2 billion deal with InnoCare Pharma hands Zenas rights to a BTK inhibitor in late-stage testing for multiple sclerosis and two other immune medicines in earlier development.

Immune reset: How T cell engagers can change the autoimmune treatment landscape

Boehringer Ingelheim drug wins FDA OK in tough-to-treat lung disease

The clearance makes Jascayd the first new drug for idiopathic pulmonary fibrosis in over a decade, but some analysts see it as a “modest” advance in care.

Drugs from China are reshaping biotech. Track the licensing deals here.

Zenas’ deal is the second involving InnoCare and a U.S. or Europe-based drugmaker this year, following a pact with Prolium Bioscience in January.

Lexeo says FDA open to speedier approval of rare disease gene therapy

The agency will consider a submission that includes pooled data from ongoing studies, a decision analysts viewed as a notable, additional sign of regulatory flexibility for gene therapies.